PMID- 25327832
OWN - NLM
STAT- MEDLINE
DCOM- 20150722
LR  - 20181202
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Linking)
VI  - 15
IP  - 1
DP  - 2015 Jan
TI  - Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
PG  - 79-94
LID - 10.1517/14712598.2015.972361 [doi]
AB  - INTRODUCTION: Patients with primary glioblastoma (GBM) have a dismal prognosis 
      despite standard therapy, which can induce potentially deleterious side effects. 
      Arming the immune system is an alternative therapeutic approach, as its cellular 
      effectors and inherent capacity for memory can be utilized to specifically target 
      invasive tumor cells, while sparing collateral damage to otherwise healthy brain 
      parenchyma. AREAS COVERED: Active immunotherapy is aimed at eliciting a specific 
      immune response against tumor antigens. Dendritic cells (DCs) are one of the most 
      potent activators of de novo and recall immune responses and are thus a vehicle 
      for successful immunotherapy. Currently, investigators are optimizing DC vaccines 
      by enhancing maturation status and migratory potential to induce more potent 
      antitumor responses. An update on the most recent DC immunotherapy trials is 
      provided. EXPERT OPINION: Targeting of unique antigens restricted to the tumor 
      itself is the most important parameter in advancing DC vaccines. In order to 
      overcome intrinsic mechanisms of immune evasion observed in GBM, the future of 
      DC-based therapy lies in a multi-antigenic vaccine approach. Successful targeting 
      of multiple antigens will require a comprehensive understanding of all 
      immunologically relevant oncological epitopes present in each tumor, thereby 
      permitting a rational vaccine design.
FAU - Batich, Kristen A
AU  - Batich KA
AD  - Duke Brain Tumor Immunotherapy Program, Division of Neurosurgery, Department of 
      Surgery ; Durham, NC 27710 , USA.
FAU - Swartz, Adam M
AU  - Swartz AM
FAU - Sampson, John H
AU  - Sampson JH
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20141018
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Epitopes)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Brain Neoplasms/immunology/pathology/*therapy
MH  - Cancer Vaccines/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Combined Modality Therapy
MH  - Dendritic Cells/immunology/*transplantation
MH  - Epitopes/immunology
MH  - Glioblastoma/immunology/pathology/*therapy
MH  - Humans
MH  - Immunotherapy, Adoptive/*methods
MH  - Neoplasm Invasiveness
MH  - Tumor Escape
OTO - NOTNLM
OT  - EGFR variant III
OT  - antigen escape
OT  - dendritic cell
OT  - glioblastoma
OT  - immunotherapy
OT  - tumor-specific antigen
EDAT- 2014/10/21 06:00
MHDA- 2015/07/23 06:00
CRDT- 2014/10/21 06:00
PHST- 2014/10/21 06:00 [entrez]
PHST- 2014/10/21 06:00 [pubmed]
PHST- 2015/07/23 06:00 [medline]
AID - 10.1517/14712598.2015.972361 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2015 Jan;15(1):79-94. doi: 10.1517/14712598.2015.972361. 
      Epub 2014 Oct 18.